Keytruda (pembrolizumab)

Pembrolizumab, marketed as Keytruda by Merck, is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). By blocking PD-1, pembrolizumab restores T-cell mediated anti-tumor activity. FDA approval records and prescribing information document its role across multiple solid tumors and hematologic malignancies.

• Non-small cell lung cancer — multiple lines and settings per FDA label history.
• Melanoma — including adjuvant treatment documented in regulatory records.
• Head and neck squamous cell carcinoma — per FDA-approved indications.
• Class-wide solid tumor indications where MSI-H/dMMR or TMB-H biomarkers are present, as listed in FDA databases.
• Additional hematologic and solid tumor settings tracked through ongoing supplemental approvals.

Pembrolizumab competes within the PD-1/PD-L1 inhibitor class alongside nivolumab (Opdivo), atezolizumab, durvalumab, and others documented in FDA records. Differentiation occurs through label breadth, trial evidence, combination regimens, and biomarker-defined populations—not through unsourced market share claims. Combination strategies with chemotherapy, targeted agents, and other immunotherapies appear extensively in ClinicalTrials.gov registrations.

• First FDA approval in advanced melanoma documented in Drugs@FDA approval history.
• Subsequent supplemental approvals across lung, bladder, gastric, and other indications in FDA databases.
• Biomarker-defined approvals for MSI-H/dMMR and TMB-H populations per FDA labeling.
• Ongoing supplemental applications tracked through FDA approval records and company SEC disclosures.

• Merck